Safety and Efficacy of Infliximab in Palmoplantar Psoriasis

This study has been completed.

Study NCT00629772 Information provided by Innovaderm Research Inc.

First Received on February 27, 2008. Last Updated on September 1, 2011 History of Changes

Results First Received: April 14, 2010

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Crossover Assignment; Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor); Primary Purpose: Treatment
Condition:	Palmoplantar Psoriasis
Interventions:	Drug: Placebo Drug: Infliximab

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Placebo Then Infliximab	Placebo at weeks 0, 2, 8 during the first intervention period and infliximab 5mg/kg at weeks 14, 16 and 20 during second intervention period.
Infliximab	Infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22.

Participant Flow for 2 periods

Period 1: First Intervention - Day 0 - Week 14

	Placebo Then Infliximab	Infliximab
STARTED	12	12
COMPLETED	12	12
NOT COMPLETED	0	0

Period 2: Second Intervention Week 14 - Week 26

	Placebo Then Infliximab	Infliximab
STARTED	12 ^[1]	12
COMPLETED	11	10
NOT COMPLETED	1	2
Adverse Event	1	1
Lack of Efficacy	0	1

[1]	Patient withdrew at Week 14 and therefore never received infliximab.

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Placebo Then Infliximab	Placebo at weeks 0, 2, 8 during the first intervention period and infliximab 5mg/kg at weeks 14, 16 and 20 during second intervention period.
Infliximab	Infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22.

Baseline Measures

	Placebo Then Infliximab	Infliximab	Total
Number of Participants [units: participants]	12	12	24
Age [units: participants]
<=18 years	0	0	0
Between 18 and 65 years	11	9	20
>=65 years	1	3	4
Age [units: years] Mean ± Standard Deviation	49.92 ± 14.74	57.83 ± 12.42	53.87 ± 13.92
Gender [units: participants]
Female	8	7	15
Male	4	5	9
Region of Enrollment [units: participants]
Canada	12	12	24
Modified Palmoplantar Pustulosis Area and Severity Index (m-PPPASI) ^[1] [units: Units on a scale] Mean ± Standard Deviation	26.7 ± 12.4	24.1 ± 11.4	25.4 ± 11.7
Dermatology Life Quality Index (DLQI) ^[2] [units: Units on a scale] Mean ± Standard Deviation	11.9 ± 6.9	9.8 ± 4.4	10.8 ± 5.8
Physician's Global Assessment (PGA) ^[3] [units: Units on as scale] Mean ± Standard Deviation	3.8 ± 0.6	3.5 ± 0.7	3.7 ± 0.6
Palmoplantar Psoriasis Surface Area PPSA ^[4] [units: Percentage of affected area] Mean ± Standard Deviation	40.4 ± 21.6	37.1 ± 21.0	38.8 ± 20.9

[1]	m-PPPASI = (E + I + D) Area X 0.2 (R palm) + (E + I + D) Area X 0.2 (L palm) + (E + I + D) Area X 0.3 (R sole) + (E + I + D) Area X 0.3 (L sole). Erythema, induration and desquamation are evaluated on a scale of 0 to 4 while area is evaluated on a scale of 0 to 6. The PPASI score can vary from 0 (absence of disease) to 72 (most severe palmoplantar psoriasis possible).
[2]	Impact on quality of life with the Dermatology Life Quality Index (DLQI) The aim of the questionnaire is to measure how much a patient's skin problem has affected their life over the previous week. 0-1 = no effect at all on patient's life 2-5 = small effect on patient's life 6-10 = moderate effect on patient's life 11-20 = very large effect on patient's life 21-30 = extremely large effect on patient's life
[3]	Efficacy by comparing the mean Physician's Global Assessment(PGA). 0 = clear 1 = almost clear 2 = Mild 3 = Moderate 4 = Severe 5 = Very severe
[4]	Efficacy by comparing the mean percent PPSA. The surface affected by psoriasis on palms and soles is estimated on the day of the visit as a percentage of the total surface of palms and soles affected by psoriasis. Each palm represents 20% and each sole 30%. As a rule of thumb half a palm equals 10% of the total surface area of palm and soles. A sole completely covered with psoriasis would have a PPSA of 30% (if the other sole and the palms are unaffected) while a palm completely covered with psoriasis would have a PPSA of 20% (if the other palm and the soles are unaffected).

Outcome Measures

Show All Outcome Measures

1. Primary:

75% Improvement in Modified Palmoplantar Pustulosis Area and Severity Index (m-PPPASI) From Day 0 [ Time Frame: 14 weeks ]

Show Outcome Measure 1

2. Secondary:

Number of Adverse Events at Week 14 [ Time Frame: 14 weeks ]

Show Outcome Measure 2

3. Secondary:

Mean Dermatology Life Quality Index (DLQI) at Week 14 [ Time Frame: 14 weeks ]

Show Outcome Measure 3

4. Secondary:

Mean Percent Palmoplantar Psoriasis Surface Area (PPSA) at Week 14 [ Time Frame: 14 weeks ]

Show Outcome Measure 4

5. Secondary:

Mean Physician's Global Assessment (PGA) at Week 14 [ Time Frame: 14 weeks ]

Show Outcome Measure 5

6. Secondary:

Mean Percent Improvement in Modified Palmoplantar Pustulosis Area and Severity Index (m-PPPASI) at Week 26 [ Time Frame: Baseline, 26 weeks ]

Show Outcome Measure 6

7. Secondary:

Mean Percent Improvement in Dermatology Life Quality Index (DLQI) at Week 26 [ Time Frame: Baseline, 26 weeks ]

Show Outcome Measure 7

8. Secondary:

Mean Percent Improvement in Physician's Global Assessment (PGA) at Week 26 [ Time Frame: Baseline, 26 weeks ]

Show Outcome Measure 8

9. Secondary:

Mean Percent Improvement in Palmoplantar Psoriasis Surface Area (PPSA) at Week 26 [ Time Frame: Baseline, 26 weeks ]

Show Outcome Measure 9

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The lack of validated scales to specifically assess severity of palmoplantar psoriasis. The study was powered to detect a difference of 55 percentage points.

Results Point of Contact:

Name/Title: Annie Levesque
Organization: Innovaderm Research
phone: 514 521 4285 ext 222
e-mail: alevesque@innovaderm.ca

No publications provided

Responsible Party:	Innovaderm Research Inc.
ClinicalTrials.gov Identifier:	NCT00629772 History of Changes
Other Study ID Numbers:	Inno-6003, P-05121
Study First Received:	February 27, 2008
Results First Received:	April 14, 2010
Last Updated:	September 1, 2011
Health Authority:	Canada: Health Canada